PT2940014T - Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo - Google Patents
Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmoInfo
- Publication number
- PT2940014T PT2940014T PT13867650T PT13867650T PT2940014T PT 2940014 T PT2940014 T PT 2940014T PT 13867650 T PT13867650 T PT 13867650T PT 13867650 T PT13867650 T PT 13867650T PT 2940014 T PT2940014 T PT 2940014T
- Authority
- PT
- Portugal
- Prior art keywords
- suppressant
- isoindole
- dihydro
- derivative
- pharmaceutical composition
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746980P | 2012-12-28 | 2012-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2940014T true PT2940014T (pt) | 2018-11-28 |
Family
ID=51021712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT13867650T PT2940014T (pt) | 2012-12-28 | 2013-12-26 | Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9758508B2 (enExample) |
| EP (2) | EP2940014B1 (enExample) |
| JP (2) | JP6325573B2 (enExample) |
| KR (1) | KR102009163B1 (enExample) |
| CN (1) | CN104995184B (enExample) |
| AU (3) | AU2013371146C1 (enExample) |
| BR (1) | BR112015015477B1 (enExample) |
| CA (1) | CA2896711C (enExample) |
| DK (1) | DK2940014T3 (enExample) |
| ES (2) | ES2696700T3 (enExample) |
| MX (2) | MX386542B (enExample) |
| PL (1) | PL2940014T3 (enExample) |
| PT (1) | PT2940014T (enExample) |
| RU (2) | RU2671847C2 (enExample) |
| WO (1) | WO2014104757A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013467A (es) | 2010-05-20 | 2013-04-29 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de trk cinasa. |
| PT2940014T (pt) | 2012-12-28 | 2018-11-28 | Crystalgenomics Inc | Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo |
| WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| MX2019006288A (es) | 2016-12-03 | 2020-10-01 | Juno Therapeutics Inc | Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa. |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US20180344702A1 (en) * | 2017-02-21 | 2018-12-06 | Aptose Biosciences Inc. | Methods for treating patients with hematologic malignancies |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| JP2022509257A (ja) * | 2018-11-30 | 2022-01-20 | アプトース バイオサイエンシズ インコーポレイテッド | ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240091226A1 (en) * | 2021-01-05 | 2024-03-21 | Sumitomo Pharma Oncology, Inc. | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor |
| US11926625B2 (en) * | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1379511B1 (en) * | 2001-04-12 | 2005-07-20 | F. Hoffmann-La Roche Ag | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| MXPA05013076A (es) * | 2003-06-02 | 2006-03-09 | Abbott Lab | Compuestos de isoindolina-1-ona como inhibidores de cinasa. |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP1880993A4 (en) * | 2005-04-19 | 2009-12-30 | Kyowa Hakko Kirin Co Ltd | NITROGENIC HETEROCYCLIC COMPOUND |
| WO2007047646A2 (en) * | 2005-10-14 | 2007-04-26 | Janssen Pharmaceutica, N.V. | Substituted dihydro-isoindolones useful in treating kinase disorders |
| CN101405001A (zh) | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| EP2205564B1 (en) * | 2007-10-23 | 2014-07-30 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
| WO2012014017A1 (en) | 2010-07-30 | 2012-02-02 | Poly Medicure Limited | Catheter introducer |
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| PT2940014T (pt) | 2012-12-28 | 2018-11-28 | Crystalgenomics Inc | Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
-
2013
- 2013-12-26 PT PT13867650T patent/PT2940014T/pt unknown
- 2013-12-26 BR BR112015015477-8A patent/BR112015015477B1/pt active IP Right Grant
- 2013-12-26 KR KR1020157018342A patent/KR102009163B1/ko active Active
- 2013-12-26 DK DK13867650.7T patent/DK2940014T3/en active
- 2013-12-26 CA CA2896711A patent/CA2896711C/en active Active
- 2013-12-26 US US14/655,954 patent/US9758508B2/en active Active
- 2013-12-26 AU AU2013371146A patent/AU2013371146C1/en active Active
- 2013-12-26 JP JP2015550315A patent/JP6325573B2/ja active Active
- 2013-12-26 WO PCT/KR2013/012204 patent/WO2014104757A1/ko not_active Ceased
- 2013-12-26 RU RU2015124381A patent/RU2671847C2/ru active
- 2013-12-26 MX MX2015008396A patent/MX386542B/es unknown
- 2013-12-26 EP EP13867650.7A patent/EP2940014B1/en active Active
- 2013-12-26 RU RU2018138028A patent/RU2018138028A/ru unknown
- 2013-12-26 MX MX2021011563A patent/MX2021011563A/es unknown
- 2013-12-26 ES ES13867650T patent/ES2696700T3/es active Active
- 2013-12-26 ES ES18190153T patent/ES2929906T3/es active Active
- 2013-12-26 EP EP18190153.9A patent/EP3428161B1/en active Active
- 2013-12-26 PL PL13867650T patent/PL2940014T3/pl unknown
- 2013-12-26 CN CN201380068623.6A patent/CN104995184B/zh active Active
-
2017
- 2017-08-30 US US15/691,432 patent/US10604508B2/en active Active
-
2018
- 2018-04-12 JP JP2018076877A patent/JP6596537B2/ja active Active
- 2018-08-10 AU AU2018214134A patent/AU2018214134B2/en active Active
-
2020
- 2020-02-14 US US16/791,753 patent/US11230539B2/en active Active
- 2020-02-27 AU AU2020201431A patent/AU2020201431B2/en active Active
-
2022
- 2022-07-22 US US17/871,458 patent/US20220380346A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2940014T (pt) | Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo | |
| ZA201406233B (en) | Pharmaceutical composition and administration thereof | |
| IL237839A0 (en) | History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| IL236024A (en) | The history of benzimidazole-proline and its pharmaceutical preparations | |
| IL235767A (en) | Preserved pyrolidines, pharmaceuticals containing them and their uses | |
| IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
| PL3181122T3 (pl) | Kompozycja farmaceutyczna dazatynibu | |
| IL237072B (en) | History of isoquinolinone, their preparation and pharmaceutical preparations containing them | |
| IL235414A (en) | The history of pyrolotriazinone, their preparation and their pharmaceutical preparations | |
| IL237073A (en) | History of pyridopyrimidine, their preparation and their pharmaceutical preparations | |
| IL238060B (en) | 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them | |
| IL238825B (en) | The history of heterocyclics, their preparation and pharmaceutical preparations containing them | |
| IL232035A (en) | These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them | |
| ZA201505318B (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| IL233602A (en) | The history of benzamide, their preparation and their pharmaceutical preparations | |
| IL233529A (en) | 1, 5-Naphthyridine derivatives and lactose-containing pharmacological preparations | |
| IL232577A0 (en) | The history of morpholinylbenzotriazine, their preparation and pharmaceutical preparations containing them | |
| EP2924042A4 (en) | BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL233825A (en) | H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines | |
| IL239054A0 (en) | History of azaquinazoline carboxamide, their preparation and pharmaceutical preparations containing them | |
| IL235955A0 (en) | The history of benzothiophene, their preparation and pharmaceutical preparations containing them | |
| IL246298A0 (en) | History of piperidine, their preparation and pharmaceutical preparations containing them | |
| IL231699A (en) | History of benzyl piperidine, their preparation and their pharmaceutical preparations | |
| IL228705A (en) | Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them |